Optimizing androgen deprivation therapy with radiation therapy for aggressive localized and locally advanced prostate cancer
Radiation therapy with androgen deprivation therapy (ADT) has historically been one of the
mainstays of treatment for intermediate-and high-risk prostate cancer. The benefit of ADT
likely derives from both enhancing local control and inhibiting micrometastatic disease.
While level 1 evidence has demonstrated the benefits of 4–6 months of ADT for all men with
intermediate-risk disease, further stratification of intermediate-risk prostate cancer into
favorable and unfavorable subgroups indicates that ADT may not be necessary for favorable …
mainstays of treatment for intermediate-and high-risk prostate cancer. The benefit of ADT
likely derives from both enhancing local control and inhibiting micrometastatic disease.
While level 1 evidence has demonstrated the benefits of 4–6 months of ADT for all men with
intermediate-risk disease, further stratification of intermediate-risk prostate cancer into
favorable and unfavorable subgroups indicates that ADT may not be necessary for favorable …